Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishing the Clinical Utility of ClarityDX Prostate

NCT06678828 is registered in ClinicalTrials.gov with Nanostics as lead sponsor.

NCT NCT06678828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishing the Clinical Utility of ClarityDX Prostate
Lead sponsor
Nanostics
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
April 14, 2025
Completion date
December 31, 2028
Enrollment
1,450 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer screening, prostate cancer screening decision